THIS IS AN ADVERTISING PROMOTIONA classic American business investment question that is often asked is where is the sizzle? It is a great question to ask - what really adds value to this? In the case of Allergy Therapeutics (AGY:AIM), the answer is the Pollinex Quattro platform and the Virus Like Particle (VLP) Peanut allergy vaccine candidate. Success or significant progress in either of these pi

A classic American business investment question that is often asked is where is the sizzle? It is a great question to ask - what really adds value to this? In the case of Allergy Therapeutics (AGY:AIM), the answer is the Pollinex Quattro platform and the Virus Like Particle (VLP) Peanut allergy vaccine candidate. Success or significant progress in either of these pipeline areas is likely to substa

Shares in commercial biotechnology company Allergy Therapeutics (AGY:AIM) jumped 20% to 40p after it announced positive results from an exploratory study of its treatment for grass allergies.The G309 field study involved two dosing courses of six injections over six and 14 weeks and demonstrated a 'statistically significant' improvement of 29.1% and 38.1% respectively compared with the placebo ind

UK stocks built on their gains on Thursday after the Bank of England kept interest rates close to zero while noting inflation was likely to top its 2% expectation but only 'temporarily'.The nine members of the Monetary Policy Committee voted unanimously to keep rates on hold, while the vote to maintain its £875 billion bond-buying programme was nodded through by eight votes to one.At 4.30pm the b

UK stocks continued their advance on Thursday after the Bank of England kept interest rates close to zero while noting inflation was likely to top its 2% expectation but only 'temporarily'.The nine members of the Monetary Policy Committee voted unanimously to keep rates on hold, while the vote to maintain its £875 billion bond-buying programme was nodded through by eight votes to one.By 12.30pm t

The UK's major shares made a quiet start to trading on Thursday with investors happy to sit tight ahead of the Bank of England's monthly interest rate call, due at 11am this morning.The Bank of England is expected to leave benchmark interest rates unchanged, but investors will look for hints of inflation pressures, which broke above the central bank's 2% target in May. Investors increasingly want

A company which provides important services to pharmaceutical companies has the potential to become a much bigger name in the future, thanks to the way the drugs industry is going.Ergomed (ERGO:AIM) may only be worth £102m at the moment, yet a recent strategy shift places the company in a much stronger position and analysts certainly believe earnings are going to explode over the coming years.Hav

For people who love the warmer months, allergies can really get you down, whether it's the constant sneezing, the itchy eyes or the endlessly runny nose while sprinting for the bus.One company trying to eradicate the frustrating side-effects of allergies is Allergy Therapeutics (AGY:AIM), a business which generated £69.9m in revenue in the 12 months to 30 June 2017.It sells proprietary and third

Risk appetite returns on Thursday following the US Federal Reserve's interest rate hike, investors taking it as a dovish signal that the Fed is going to tighten monetary policy only cautiously as the economy improves.While the FTSE 100 races 52.4 points higher to 7,421 early on, Sainsbury's (SBRY) cheapens 1.7% to 266.9p on a rather disappointing fourth quarter trading statement. This shows like-f

The Alternative Investment Market (AIM) turned 21 in June yet many investors remain conflicted about the London Stock Exchange's (LSE) junior market. For some AIM has really matured into adulthood, others believe it remains the difficult child of the stock market family and is best avoided.AIM was launched on 19 June 1995 with a clear objective to attract small companies from around the world who

Allergy vaccines specialist Allergy Therapeutics (AGY:AIM) reports revenue for its financial year to 30 June will be slightly ahead of expectations at £48.5 million thanks to market share gains.Shares are up 4% to 19.7p.The company's revenues are 12% higher than the £43.2 million posted last year, despite the negative impact of a weakening euro throughout the majority of 2016.At constant currenc

Investors appear to be holding fire ahead of tomorrow's call on UK interest rates rather than taking their cue from strong gains in the US and Asia overnight with the FTSE 100 down 0.26% at 6,663.24.Housebuilders post modest falls as Barratt Developments (BDEV) posts a positive pre-close update but sounds a downbeat tone on Brexit noting 'the immediate outlook for our industry is less clear and it

The markets appear to be treading water ahead of the key US non-farm payrolls release later with the FTSE 100 up a modest 0.1% to 6540.11. The move follows falls in US and Asia overnight.Financials are under pressure with Royal Bank of Scotland (RBS) down 1.9% to 155.6p and Aviva (AV.) falling 0.76% to £13.07 but mining stocks provide some support on stronger metals prices with Rio Tinto (RIO) le

Fears over another bad day on the UK stock market have been scotched after the FTSE 100 got off to a quiet start. It slipped back 46 points, or 0.7%, to 6,092 amid efforts by Chancellor George Osborne to maintain a sense of calm following last week's Brexit vote.Osborne says there won't be an emergency budget and insists the UK economy is 'fundamentally strong'. Sterling fell a further 2% prior to

The onset of spring means months of itchy eyes and sneezing for many people. The number suffering from allergies, such as hay fever caused by grass and tree pollen, is set to reach one in four of the population, according to eye health specialist Bausch & Lomb. Investors can play the allergy treatment trend via several stocks.More than 150 million people in Europe have at least one allergy, making

London shares are on the retreat in early trade on Tuesday as jittery investors mull a mixed bag of corporate results and fret over weak trade figures coming out of China. The FTSE 100 index slidfes around 65 points, or roughly 1%, to 6,120, matching similar gloom across Europe and on Asian markets overnight. Wall Street closed up.Kantar Worldpanel's latest grocery share figures reveal 0.5% year-o

London shares rally sharply in early trading on Tuesday as gains among supermarkets and resources stocks provide strong direction for a string of UK companies. The fact that both Wall Street and Asian markets also rose adds to the run higher. The FTSE 100 index jumps more than 100 points, or 1.7%, to 6,252, while midcaps leap back over the 17,000 mark, the FTSE 250 hitting 17,056.A deluge of corpo

London shares creep a fraction higher in early trade on Thursday as investors sigh with relief as inflation risks diminish. The market had feared an early interest rate hike but these worries seem to have been over-egged. The benchmark FTSE 100 stays roughly flat at 6,671, showing a very modest 6 points improvement, moves largely matched by both the midcaps FTSE 250 index and the wider market FTSE

The FTSE 100 dives 45.65 points to 6,540 as Greece moved a step closer to leaving the eurozone over the weekend. The Greeks voted to reject the austerity conditions linked to a fresh bailout package in Sunday's referendum.Banks led the fallers in London during early trading with Royal Bank of Scotland (RBS) diving 2.3% to 350.7p, closely followed by a 1.8% drop by Barclays (BARC) to 258p while HSB

London's FTSE is off 13.66 points at 6,862.81, as appetite for risk remains subdued amid renewed concerns over Greece. Bucking the trend is luxury car dealer Inchcape (INCH), motoring 6.3% ahead to 787.5p after reporting its fifth consecutive year of double-digit earnings growth and a step-up in free cash flow generation. Like-for-like sales accelerated in 2014 and there's a positive outlook state